Approval · Notice of Compliance 17416 · 2015
ESOMEPRAZOLE: Notice of Compliance 17416
Issued October 22, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17416
- Date
- October 22, 2015
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- H+,K+-atpase inhibitor
- Canadian reference product
- NEXIUM (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESOMEPRAZOLE | 02438461 | Cancelled Pre Market |
| ESOMEPRAZOLE | 02438488 | Cancelled Pre Market |
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM 20 MG per TAB
- ESOMEPRAZOLE MAGNESIUM 40 MG per TAB